{"filings":[{"id":870757,"accession_number":"0001193125-26-258466","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2026-06-05T12:10:26+00:00","items":["5.07"],"status":"ready","headline":"PMV Pharma annual meeting reelects Mack and Stelzer as Class III directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David H. Mack, Ph.D. elected with 15,693,907 for, 6,248,461 withheld; Laurie Stelzer with 11,261,111 for, 10,681,257 withheld.","Non-binding say-on-pay resolution approved: 15,015,578 for, 6,468,718 against, 458,072 abstain.","Ernst & Young ratified as independent auditor for FY2026: 28,379,108 for, 536,302 against, 2,370 abstain.","Broker non-votes on director election and say-on-pay totaled 6,975,412 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22728,"accession_number":"0001193125-26-218225","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2026-05-12T12:00:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma Q1 net loss $18M; rezatapopt NDA for ovarian cancer targeted for Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and securities $93.5M at March 31, 2026; net cash used in operations $19.7M for Q1.","Net loss $18M for Q1 2026 vs $17.4M in Q1 2025; R&D expenses decreased to $15.3M.","Confirmed ORR 44% (32/72) for rezatapopt in platinum-resistant/refractory TP53 Y220C ovarian cancer from SGO April 2026.","FDA granted Orphan Drug Designation for rezatapopt in TP53 Y220C positive ovarian cancer.","Phase 1 results published in NEJM; NDA submission planned in Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107428,"accession_number":"0001193125-26-095094","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma reports FY2025 net loss of $77.7M; reaffirms NDA filing for rezatapopt in Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and securities $112.9M at Dec 2025 (down from $183.3M); runway to end of Q2 2027.","Net loss $77.7M for FY2025 vs $58.7M in 2024; net cash used in ops $73.6M (vs $51.3M).","R&D expenses $69.9M (up from $58.5M) on rezatapopt trial costs; G&A $16.3M (down from $26.9M).","PYNNACLE Phase 2 enrollment on track; NDA submission for ovarian cancer planned Q1 2027.","Rezatapopt granted FDA Orphan Drug Designation for TP53 Y220C positive ovarian cancer; Phase 1 in NEJM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123773,"accession_number":"0001193125-25-276000","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma reports Q3 2025 net loss of $21.1M; highlights 34% ORR with rezatapopt in PYNNACLE study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities of $129.3M as of Sept 30, 2025; cash runway to end of Q1 2027.","Overall response rate of 34% (35/103 patients) in Phase 2 PYNNACLE study; 46% ORR in ovarian cancer cohort with median duration of response of 8.0 months.","Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned for Q1 2027.","Net loss for Q3 2025 was $21.1M vs $19.2M in Q3 2024, driven by increased R&D costs of $18.2M.","R&D expenses increased to $18.2M from $16.9M due to advancement of rezatapopt program; G&A decreased to $4.3M from $4.9M."],"consensus_eps_estimate":-0.4106,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140458,"accession_number":"0001193125-25-199857","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PMV Pharma reports 33% ORR for rezatapopt in TP53 Y220C tumors; NDA for ovarian cancer planned Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Overall ORR 33% (32/97 evaluable patients) across 8 tumor types; median duration of response 6.2 months.","Ovarian cancer cohort: 43% ORR (19/44), median DOR 7.6 months, includes one confirmed complete response.","Safety profile manageable: most TRAEs Grade 1-2, no discontinuations due to Grade 3 AST/ALT elevations, 3.7% discontinuation rate.","FDA feedback supports NDA for platinum resistant/refractory ovarian cancer; plan to enroll 20-25 more patients by Q1 2026.","NDA submission for rezatapopt in ovarian cancer targeted for end of Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140457,"accession_number":"0000950170-25-104587","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma Q2 net loss $21.2M; cash $148.3M; Phase 2 interim analysis webinar Sept 10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.2M for Q2 2025 vs $1.2M in Q2 2024, due to prior-year $16.2M tax benefit from NOL sale.","Cash, equivalents, and marketable securities $148.3M as of June 30, 2025, expected runway to end of 2026.","R&D expenses $18.4M (up 26% YoY) driven by contractual research costs for rezatapopt program.","Investor webinar Sept 10 to review Phase 2 PYNNACLE interim data; ~65 patients, ~45% ovarian cancer."],"consensus_eps_estimate":-0.391,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158138,"accession_number":"0001193125-25-137497","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PMV Pharma annual meeting: say-on-pay fails; two directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding say-on-pay vote failed: 20.2M against vs 11.6M for (8.8M broker non-votes).","Director Arnold Levine elected: 26.7M for, 5.1M withheld.","Director Charles Baum elected despite 18.6M votes withheld (13.3M for).","Ratification of Ernst & Young as FY2025 auditor approved overwhelmingly (40.0M for, 0.6M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158137,"accession_number":"0000950170-25-067511","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma Q1 net loss $17.5M; Phase 2 interim data expected mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 PYNNACLE interim analysis mid-2025; data for ~50 patients with ≥18 weeks follow-up.","Cash $165.8M as of March 31, 2025 vs $183.3M Dec 31, 2024; runway to end of 2026.","Net loss Q1 2025 $17.5M ($15.3M Q1 2024); R&D expenses $17.4M vs $13.2M.","G&A expenses decreased to $4.1M from $5.0M on reduced headcount and facility spend.","Rezatapopt discovery paper published in Cancer Discovery."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176503,"accession_number":"0000950170-25-030407","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma reports FY2024 net loss of $58.7M; cash runway to end of 2026; Phase 2 interim data mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $58.7M for FY2024, compared to $69.0M in FY2023; no revenue.","Cash, cash equivalents & marketable securities of $183.3M as of Dec 31, 2024; provides cash runway to end of 2026.","Phase 2 PYNNACLE trial enrollment on track; interim analysis data expected mid-2025; NDA submission anticipated by end of 2026.","Discontinued enrollment in Phase 1b combination arm of rezatapopt with pembrolizumab due to lack of clinically meaningful benefit.","Enrollment commenced in investigator-initiated Phase 1b study of rezatapopt in relapsed/refractory AML/MDS with TP53 Y220C mutation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193356,"accession_number":"0000950170-24-122816","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma Q3 net loss $19.2M; cash runway to end 2026; Phase 2 enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.2M in Q3 2024 vs $16.6M Q3 2023; R&D spend rose to $16.9M on trial costs.","Cash $197.9M at Sep 30, 2024; provides expected runway to end of 2026.","Phase 2 PYNNACLE trial enrollment on track; >75% sites activated; interim analysis expected mid-2025.","Investigator-initiated Phase 1b of rezatapopt in AML/MDS with MD Anderson and MSKCC; enrollment planned Q1 2025.","Discontinued Phase 1b combination arm with pembrolizumab due to dose-limiting toxicities and limited benefit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209704,"accession_number":"0000950170-24-093345","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["1.02","2.02","9.01"],"status":"ready","headline":"PMV Pharma Q2 net loss $1.2M on $16.2M tax benefit; cash $212.9M; PYNNACLE Phase 2 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $1.2M from $17.4M YoY due to $16.2M income tax benefit from NOL sale.","Cash, equivalents, and marketable securities $212.9M; net cash used in operations $17.8M in H1 2024.","Phase 2 monotherapy enrollment on track; >60% sites activated; interim analysis expected by mid-2025.","Phase 1b rezatapopt/pembrolizumab combo adjusted to exclude KRAS SNV; DLTs observed at 1000 mg, then escalated back.","Lease termination at Princeton HQ with $1.42M fee; relocation to smaller space to reduce costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227843,"accession_number":"0001193125-24-156745","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PMV Pharma shareholders elect directors, approve say-on-pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Kirsten Flowers and Carol Gallagher elected with 35.7M and 27.1M votes for, respectively.","Non-binding advisory vote on executive compensation approved: 34.5M for, 1.1M against, 0.8M abstain.","Ratification of Ernst & Young as independent auditor for FY2024 passed with 43.5M for, 90.9K against.","Broker non-votes: 7.2M on director elections and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227842,"accession_number":"0000950170-24-056294","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma Q1 loss narrows to $15.3M; Phase 2 PYNNACLE trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.3M vs $19.1M YoY; cash $213.1M, expected runway to end of 2026.","First patient dosed in registrational Phase 2 PYNNACLE trial for rezatapopt (TP53 Y220C/KRAS wild-type).","Phase 1 ovarian cancer data: 7/15 confirmed partial responses, median duration 7 months.","R&D expenses $13.2M (down from $15.1M); G&A $5.0M (down from $6.4M).","Net cash used in operations $16.2M vs $15.0M in Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246636,"accession_number":"0000950170-24-023058","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma FY 2023 net loss $69.0M; rezatapopt Phase 2 on track for Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities $228.6M at Dec 31, 2023; cost savings from workforce reduction extend runway to end 2026.","Rezatapopt Phase 1 data: confirmed ORR 38% at RP2D (2000 mg daily), median DOR 7 months in TP53 Y220C/KRAS WT patients.","Registrational Phase 2 portion of PYNNACLE trial on track to initiate Q1 2024; FDA alignment on RP2D and key Phase 2 design elements.","Phase 1 analysis in ovarian cancer subgroup selected as late-breaking oral presentation at 2024 SGO Annual Meeting on March 18.","Net loss $69.0M vs $73.3M in 2022; R&D expenses $55.9M, G&A $24.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246635,"accession_number":"0001193125-24-010177","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"PMV Pharma cuts workforce 30%, extends cash runway to end of 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~30% to prioritize PC14586 development and streamline operations.","Unaudited cash, cash equivalents, and marketable securities of ~$229M as of Dec 31, 2023.","Expected non-recurring charges of ~$1.4M for employee severance and benefits, mainly in Q1 2024.","Cash runway now expected to extend to end of 2026 due to cost savings.","Registrational Phase 2 trial for PC14586 remains on track to initiate in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246634,"accession_number":"0001193125-24-003348","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PMV Pharma appoints new CFO, CMO departs; leadership reshuffled as late-stage program advances","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Carulli promoted to CFO; Winston Kung transitions to advisor through March 2024.","Leila Alland steps down as CMO; remains advisor through March 2024 at $500/hour.","Deepika Jalota appointed Chief Development Officer; Marc Fellous named SVP Clinical Development.","Robert Ticktin expands role to include Operations; Tim Smith adds Corporate Development duties.","Carulli receives $370K base salary, 40% bonus target, and severance policy coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264059,"accession_number":"0000950170-23-061552","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma reports Q3 loss, PC14586 Phase 1 data shows 38% ORR at RP2D","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss 9mo $53.2M vs $54.0M YoY; cash $238.1M as of Sep 30, 2023.","PC14586 PYNNACLE: 38% ORR at 2000 mg RP2D (6/16 evaluable, TP53 Y220C/KRAS wild-type).","Median duration of response 7 months across ovarian, breast, prostate, SCLC, endometrial cancers.","Registrational Phase 2 trial to start Q1 2024; RP2D aligned with FDA in Q3 2023 meeting.","Raised $35.1M net via ATM facility during 9mo; R&D expenses increased to $42.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264058,"accession_number":"0001193125-23-255083","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PMV Pharma: PC14586 Phase 1 shows 38% ORR at RP2D; registrational Phase 2 planned early 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed ORR 38% (6/16) at RP2D 2000 mg daily in TP53 Y220C/KRAS wild-type patients; median DoR 7 months.","Responses across ovarian, breast, prostate, lung, endometrial cancers; 34% ORR in efficacious dose range (13/38).","Well tolerated: most TRAEs Grade 1-2 (nausea, vomiting, creatinine increase); only 3% discontinuation due to TRAE.","RP2D selected after End of Phase 1 meeting with FDA in Q3 2023; Phase 2 registrational trial to start early 2024.","Study enrolled heavily pretreated patients (median 3 prior lines); no approved therapies targeting p53 currently exist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264057,"accession_number":"0001193125-23-254135","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PMV Pharma to present updated Phase 1 PC14586 data at AACR-NCI-EORTC; KOL webinar planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated Phase 1 data cutoff Sep 5, 2023; abstract with May 1 cutoff published.","Poster session October 12, 2023 12:30-4:00 PM ET at AACR-NCI-EORTC conference.","PC14586 targets p53 Y220C mutation in advanced solid tumors; PYNNACLE study ongoing.","KOL webinar October 12 at 4:00 PM ET with regulatory update included.","Data also discussed in Chemistry in Cancer Research Town Hall and Concurrent Session 8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281293,"accession_number":"0000950170-23-040151","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma Q2 net loss $17.4M; FDA aligns on Phase 2 dose for PC14586","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & marketable securities $218.8M as of June 30, 2023, down from $277.4M a year ago.","Net loss for six months ended June 30, 2023 was $36.6M vs. $35.7M in same period 2022.","R&D expenses rose to $28.9M for six months, driven by headcount and clinical costs for PC14586.","FDA alignment obtained on recommended Phase 2 dose and key elements of registrational trial; Phase 1 data update expected 2H 2023.","Appointed Dr. Masha Poyurovsky as Vice President of Biology; ongoing combination arm with KEYTRUDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300071,"accession_number":"0001193125-23-164011","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PMV Pharma shareholders elect directors, approve say-on-pay, and ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Class III directors Richard Heyman (28.7M for), David Mack (35.2M for), and Laurie Stelzer (34.1M for).","Non-binding advisory vote on executive compensation approved with 34.5M for, 0.8M against.","Ratified Ernst & Young as independent auditor for FY2023 with 39.9M for, 2,087 against.","All proposals passed; annual meeting held virtually on June 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300070,"accession_number":"0000950170-23-020097","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma reports Q1 net loss $19.1M; PC14586 trial advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q1 2023 $19.1M vs $18.4M Q1 2022; cash & equivalents $229.4M.","R&D expenses $15.1M (up from $11.8M) due to increased clinical costs for PC14586.","Phase 1/2 PYNNACLE study of PC14586 ongoing; next update expected in 2H 2023.","Enrollment commenced in combination arm of PC14586 with KEYTRUDA (pembrolizumab).","Net cash used in operations $15.0M vs $18.0M in prior year period."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300069,"accession_number":"0001193125-23-124381","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"PMV Pharmaceuticals adopts amended bylaws effective June 8, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended and Restated Bylaws approved by Board on April 24, 2023, effective at 2023 annual meeting.","Updates advance notice procedures for director nominations, including Rule 14a-19 compliance evidence requirement.","Revises provisions on stockholder meetings, board action by written consent, and director/committee matters to conform to Delaware law.","Also updates various provisions to conform to recent amendments to DGCL and makes ministerial clarifications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320150,"accession_number":"0000950170-23-005343","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma reports FY2022 net loss $73.3M; cash $243.5M; PC14586 update expected 2H 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $73.3M in FY2022 vs $57.8M in FY2021; R&D expenses rose to $52.0M from $36.5M.","Cash, equivalents, and marketable securities $243.5M at Dec 31, 2022, down from $314.1M.","Phase 1/2 PYNNACLE study of PC14586 ongoing; first patient enrolled in combination arm with KEYTRUDA.","WIP-1 and R273H programs put on hold; projected cash runway extended to 1H 2025.","Appointed Kirsten Flowers and Carol Gallagher to Board; promoted Michael Carulli to SVP Finance."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338292,"accession_number":"0000950170-22-022919","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma Q3 2022 net loss widens to $54M; cash at $258.9M; PC14586 trial ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for nine months ended Sep 30, 2022: $54.0M vs $39.5M YoY; cash & equivalents $258.9M (Dec 2021: $314.1M).","R&D expenses rose to $37.0M (vs $24.3M) due to PC14586 clinical costs; G&A $18.9M (vs $15.5M).","Enrollment continues in Phase 1/2 PYNNACLE trial of PC14586 for p53 Y220C advanced solid tumors.","Phase 1b combo trial with Merck's KEYTRUDA on track to initiate in Q4 2022.","Appointed Dr. Carol Gallagher to Board; brings 30 years of biotech leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338291,"accession_number":"0001193125-22-277423","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PMV Pharma appoints Dr. Carol Gallagher to board, replacing Thilo Schroeder","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thilo Schroeder resigned from board effective Nov 3, 2022; resignation not related to any disagreement.","Carol Gallagher, Pharm.D., appointed as Class I director effective Nov 3, 2022.","Gallagher has over 30 years biotech leadership and currently serves as venture partner at NEA.","She joins PMV as the company notes recent clinical proof of concept for lead candidate PC14586."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355662,"accession_number":"0000950170-22-015768","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma Q2 net loss $35.7M; cash $277.4M; PC14586 combo with KEYTRUDA planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for H1 2022: $35.7M vs $24.5M YoY; cash, cash equivalents and marketable securities $277.4M as of June 30, 2022.","R&D expenses $23.3M in H1 2022 vs $15.2M in H1 2021, driven by PC14586 clinical trial costs.","Initial PC14586 Phase 1 data presented at ASCO; entered clinical collaboration with Merck for PC14586 + KEYTRUDA combo trial starting Q4 2022.","Appointed Marc Fellous, M.D. as VP, Clinical Development and Medical Affairs; previous experience at Bayer and Roche.","Net cash used in operations $31.7M in H1 2022 vs $22.1M in H1 2021; cash burn increased 43%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373903,"accession_number":"0001193125-22-169686","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PMV Pharma reports PC14586 Phase 1 data: 32% ORR at high doses, responses in 6 tumor types","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Overall response rate (ORR) 32% (8/25) in patients receiving daily dose ≥1150 mg; 24% (8/33) across all doses.","Partial responses observed in breast, endometrial, prostate, pancreatic, ovarian, and small cell lung cancers.","Maximum tolerated dose reached at 1500 mg twice daily; common AEs included nausea, vomiting, AST/ALT increases.","Phase 2 portion of PYNNACLE study expected to start early 2023; data provide proof of concept for p53 reactivation.","Data presented at ASCO 2022 by MD Anderson investigator; first-in-class small molecule targeting p53 Y220C mutation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373902,"accession_number":"0001193125-22-168285","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PMV Pharma stockholders re-elect Levine and Baum, approve say-on-pay and one-year frequency, ratify EY","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Arnold Levine elected as Class II director with 29,469,991 FOR votes; Charles Baum with 29,134,747 FOR.","Non-binding say-on-pay approved: 32,962,908 FOR, 872,088 AGAINST.","Stockholders favored one-year frequency for future advisory votes on executive compensation (33,827,318 FOR one year).","Ernst & Young ratified as independent auditor for FY2022: 35,746,657 FOR, 4,223 AGAINST, 451 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373901,"accession_number":"0001564590-22-021434","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PMV Pharma's PC14586 shows 30% partial response in higher dose cohorts at ASCO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract reports 3/10 (30%) partial responses in patients treated in higher dose cohorts of Phase 1/2 PYNNACLE trial.","Data from 29 patients (21 evaluable) across multiple tumor types with p53 Y220C mutation; safety profile well-tolerated.","Dose-proportional increases in Cmax and AUC observed; updated data to be presented in oral session on June 7, 2022.","Company to host investor webcast on June 7 at 6:30 PM CDT to review data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373900,"accession_number":"0001564590-22-019070","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma reports Q1 2022 net loss of $18.4M; cash at $294.8M; ASCO presentation on PC14586","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.4M for Q1 2022 vs $11.6M in Q1 2021; R&D spend increased to $11.8M.","Cash, equivalents and marketable securities totaled $294.8M as of March 31, 2022, down from $314.1M at year-end 2021.","Initial Phase 1/2 data for PC14586 (p53 Y220C reactivator) selected for oral presentation at ASCO 2022 on June 7.","Continued advancement of WIP1 inhibitor and p53 mutant pipeline programs.","Net cash used in operations was $18.0M in Q1 2022 vs $12.9M in Q1 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392549,"accession_number":"0001564590-22-007858","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma reports FY2021 net loss of $57.8M; cash at $314.1M; PC14586 data expected H1 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $57.8M in FY2021 vs $34.4M in FY2020; R&D expenses $36.5M; G&A $21.8M.","Cash, cash equivalents and marketable securities $314.1M as of Dec 31, 2021 vs $361.4M Dec 31, 2020; net cash used in operations $46.6M.","Lead candidate PC14586 Phase 1/2 trial ongoing; initial Phase 1 data expected in first half of 2022.","Advanced WIP1 inhibitor program into lead optimization; appointed Kirsten Flowers to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392548,"accession_number":"0001193125-22-003158","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2022-01-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PMV Pharma appoints Kirsten Flowers to Board; Dr. Peter Thompson resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Peter Thompson resigned from the board and committees effective January 5, 2022; not related to any disagreement.","Kirsten Flowers appointed Class I director effective January 5, 2022, filling the vacancy until the 2024 annual meeting.","Ms. Flowers is Chief Commercial Officer of Kura Oncology, with prior roles at Array Biopharma and Pfizer.","Her compensation follows the Company's Outside Director Compensation Policy; an indemnification agreement was executed.","No arrangements or family relationships exist between Ms. Flowers and any other director or officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410902,"accession_number":"0001564590-21-056451","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma Q3 2021 net loss $39.5M for nine months; cash $326.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for nine months ended Sep 30, 2021: $39.5M vs $24.0M in prior-year period.","Cash, equivalents and marketable securities: $326.3M as of Sep 30, 2021; sufficient through end of 2023.","R&D expenses increased to $24.3M (from $17.8M) driven by PC14586 clinical development.","Phase 1/2 trial of p53 Y220C reactivator PC14586 data expected in first half 2022.","Appointed Tim Smith as SVP, Head of Corporate Development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410901,"accession_number":"0001193125-21-292044","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2021-10-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PMV Pharma enters $150M ATM equity distribution agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Open Market Sale Agreement with Jefferies LLC for up to $150M in gross proceeds from common stock sales.","Shares sold at prevailing market prices; Jefferies receives 3.0% commission on gross proceeds.","ATM offering conducted under shelf registration statement filed October 4, 2021.","Company may suspend or terminate agreement with 10 trading days' notice; no minimum sale obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429677,"accession_number":"0001564590-21-044128","cik":1699382,"company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","form_type":"8-K","filed_at":"2021-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PMV Pharma Q2 2021 net loss $24.5M; cash $339M; PC14586 trial enrollment ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for H1 2021 was $24.5M vs $15.2M in H1 2020.","Cash, cash equivalents & marketable securities $339.0M at June 30, 2021.","R&D expenses $15.2M (H1 2021) vs $11.8M (H1 2020) on PC14586 development.","Continued enrollment in Phase 1/2 trial of p53 Y220C reactivator PC14586.","Activated 12 clinical trial sites across leading US oncology centers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":64798096.5,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}